期刊
CIRCULATION JOURNAL
卷 77, 期 9, 页码 2209-2217出版社
JAPANESE CIRCULATION SOC
DOI: 10.1253/circj.CJ-13-0971
关键词
Epidemiology; Heart failure; Prognosis
资金
- Bayer Yakuhin, Ltd (Osaka, Japan)
- Daiichi Sankyo Co, Ltd (Tokyo, Japan)
- Dainippon Sumitomo Pharma Co, Ltd (Osaka, Japan)
- Kowa Pharmaceutical Co, Ltd (Tokyo, Japan)
- Kyowa Hakko Kirin Co, Ltd (Tokyo, Japan)
- Nippon Boehringer Ingelheim Co, Ltd (Tokyo, Japan)
- Novartis Pharma K.K. (Tokyo, Japan)
- Asahi Kasei Pharma Corporation (Tokyo Japan)
Heart failure (HF) is a global epidemic in health care and a leading cause of mortality and morbidity worldwide. In Asian countries, causes of mortality and morbidity have shifted or have been shifting from infectious diseases and/or nutritional deficiencies to lifestyle-related diseases, such as cardiovascular disease, cancers and diabetes, in conjunction with the transition from developing to developed countries during the past decades (so-called the epidemiologic transition). Because the effect of this epidemiologic transition varies among countries, the etiology, prevalence, management and outcomes of HF also differ among the countries. Thus, we need to assemble and comprehensively analyze the available evidence to date for daily HF practice in Asia and to systematically conduct future epidemiologic approaches to establishing appropriate preyention programs against the burden of HF in Asia. This review article will briefly update the epidemiology of HF in Asia.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据